
Please try another search
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
Joseph M. Chalil | 48 | 2015 | Member of Scientific Advisory Board |
Klaus Kutz | - | 2010 | Chief Medical Officer & Member of Scientific Advisory Board |
John F. Smyth | - | - | Member of Scientific Advisory Board |
James Nathanielsz | 51 | 2007 | CEO, CFO & Executive Chairman |
Julian Norman Kenyon | 77 | 2008 | Chief Scientific Officer & Director |
Ralf Brandt | 62 | 2019 | Member of Scientific Advisory Board |
Juan Antonio Marchal Corrales | - | 2016 | Member of Scientific Advisory Board |
Maria A. Garcia | - | 2016 | Member of Scientific Advisory Board |
Macarena Peran | - | 2016 | Member of Scientific Advisory Board |
Josef Zelinger | 74 | 2020 | Independent Non-Executive Director |
Joseph N. Himy | 55 | 2025 | Independent Director |
Annie Van Broekhoven | 73 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review